  We develop a methodology to create data-driven predictive digital twins for
optimal risk-aware clinical decision-making. We illustrate the methodology as
an enabler for an anticipatory personalized treatment that accounts for
uncertainties in the underlying tumor biology in high-grade gliomas, where
heterogeneity in the response to standard-of-care (SOC) radiotherapy
contributes to sub-optimal patient outcomes. The digital twin is initialized
through prior distributions derived from population-level clinical data in the
literature for a mechanistic model's parameters. Then the digital twin is
personalized using Bayesian model calibration for assimilating patient-specific
magnetic resonance imaging data and used to propose optimal radiotherapy
treatment regimens by solving a multi-objective risk-based optimization under
uncertainty problem. The solution leads to a suite of patient-specific optimal
radiotherapy treatment regimens exhibiting varying levels of trade-off between
the two competing clinical objectives: (i) maximizing tumor control
(characterized by minimizing the risk of tumor volume growth) and (ii)
minimizing the toxicity from radiotherapy. The proposed digital twin framework
is illustrated by generating an in silico cohort of 100 patients with
high-grade glioma growth and response properties typically observed in the
literature. For the same total radiation dose as the SOC, the personalized
treatment regimens lead to median increase in tumor time to progression of
around six days. Alternatively, for the same level of tumor control as the SOC,
the digital twin provides optimal treatment options that lead to a median
reduction in radiation dose by 16.7% (10 Gy) compared to SOC total dose of 60
Gy. The range of optimal solutions also provide options with increased doses
for patients with aggressive cancer, where SOC does not lead to sufficient
tumor control.
